These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12055019)

  • 1. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits.
    Hofmann T; Horstmann G; Stammberger I
    Int J Toxicol; 2002; 21(3):181-9. PubMed ID: 12055019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice.
    Stammberger I; Bube A; Durchfeld-Meyer B; Donaubauer H; Troschau G
    Int J Toxicol; 2002; 21(3):171-9. PubMed ID: 12055018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
    Luzio SD; Beck P; Owens DR
    Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics.
    Fang YM; MacKeen D; Egan JF; Zelop CM
    J Matern Fetal Neonatal Med; 2009 Mar; 22(3):249-53. PubMed ID: 19330710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
    Päivärinta M; Tapanainen P; Veijola R
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
    Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
    Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre- and postnatal development studies of lasofoxifene, a selective estrogen receptor modulator (SERM), in Sprague-Dawley rats.
    Weisenburger WP; Hagler AR; Tassinari MS
    Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):171-84. PubMed ID: 15282738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reproductive toxicity evaluation of a new camptothecin anticancer agent, CKD-602, in pregnant/lactating female rats and their offspring.
    Chung MK; Kim CY; Kim JC
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):383-95. PubMed ID: 16896929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initiation of insulin glargine in children and adolescents with type 1 diabetes.
    Tan CY; Wilson DM; Buckingham B
    Pediatr Diabetes; 2004 Jun; 5(2):80-6. PubMed ID: 15189493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin glargine (Lantus).
    Owens DR; Griffiths S
    Int J Clin Pract; 2002; 56(6):460-6. PubMed ID: 12166545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of ebrotidine on reproduction. Toxicity on fertility and general reproductive performance, embryo-fetal toxicity and peri- and postnatal toxicity.
    Romero A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):504-10. PubMed ID: 9205753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perinatal outcomes in pregnancies managed with antenatal insulin glargine.
    Egerman RS; Ramsey RD; Kao LW; Bringman JJ; Haerian H; Kao JL; Bush AJ
    Am J Perinatol; 2009 Sep; 26(8):591-5. PubMed ID: 19370512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
    Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
    Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
    Yokoyama H; Tada J; Kamikawa F; Kanno S; Yokota Y; Kuramitsu M
    Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early hypoglycaemia after accidental intramuscular injection of insulin glargine.
    Karges B; Boehm BO; Karges W
    Diabet Med; 2005 Oct; 22(10):1444-5. PubMed ID: 16176210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription of insulin glargine in primary care practices in Germany.
    Rathmann W; Haastert B; Riebel P; Schroeder-Bernhardi D; Kostev K; Huppertz E; Giani G
    Exp Clin Endocrinol Diabetes; 2007 Apr; 115(4):252-6. PubMed ID: 17479442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.